

Index

- AUTM, 157
- Balkanization, 17
- Bayh-Dole Act, 41, 53, 60, 91,
115–117, 153, 177
- biotechnology industry, i, x, xii, xiii,
xiv, xv, xvi, xviii, 3, 4, 7–11, 17,
19, 20, 22–28, 30, 33, 34, 36, 37,
39, 40, 41, 44, 46, 47, 49, 50, 52,
53, 54, 55, 56, 57, 58, 61, 62, 65,
69, 78, 85, 86, 90, 94, 119, 127,
129, 130, 132, 141, 150, 152,
177, 187, 189, 194, 195, 198,
199, 201, 202, 204, 206, 209,
210, 211–213, 216, 219, 223
- bounded rationality, 141, 143
- Callon, 192, 204–206
- centrality, 48, 71, 92, 224–225
- chaos, 142, 158, 162
- chaotic networking, 140
- closed system, 143
- co-evolution, 143
- Cohen and Boyer, 119–122, 126,
131, 137
- Coleman, 81, 173, 174, 218
- collaboration, xii, xiii, xiv, xvii, 1, 9,
10, 16, 18, 24, 32, 37, 46, 50, 65,
71, 75, 85, 88, 93, 94, 101, 105,
106, 112, 114, 115, 132, 141,
143, 144, 150, 154, 158, 160–168,
178, 187, 188, 189, 190, 192–200,
202–209, 211–217, 224
- collaborations searches, 143
- commercial interests, 17
- commercial science, 48, 179
- commercialization, 3, 5, 6, 10, 13, 20,
28, 30, 32, 37, 40, 42, 43, 45,
53, 59, 64, 75, 88, 89, 90, 91, 96,
117, 118, 119, 121, 127, 131,
132, 133, 134, 139, 152, 177,
178, 212
- communities, 26, 29, 51, 59, 67,
167, 217
- competition, xii, xiv, xvii, 18, 30, 33,
49, 60, 72, 73, 75, 86, 116, 117,
187–194, 196–209, 213, 214,
215, 223
- complex systems, 163
- complexity, xiv, 1, 141, 142, 143,
166, 167, 180, 189, 191, 208,
209, 211, 219
- consolidation, 203
- consortia, xv, 65, 78, 86, 113, 212
- continuous entrepreneurs, 97, 104
- contractual arrangements, 31
- credibility, 173, 174
- credits, 180
- dense networks, 48
- dilemma, 59, 69, 168, 191
- duality, xii, xvii, 187, 188, 192,
194, 196, 198, 205, 209–211,
213–214, 216
- dynamic capabilities, 189
- entrepreneurial scientists, xii, xv, 43,
84, 89–95, 104, 106, 111, 112,
175, 216
- entrepreneurial universities, 41, 89,
105
- entrepreneurship, xv
- equifinality, 143, 166
- equilibrium, 163
- established firms, 15
- Etzkowitz, 41, 83, 88, 140, 152,
154, 156
- evolutionary theory, 6
- exclusive licensing, 116–119, 128,
138

- exploitation, xviii, 34, 78, 130, 190, 192–193, 199–200, 206, 209, 214, 221–222, 226
- exploration, xviii, 34, 78, 93, 114, 160, 166, 191–192, 199–202, 206, 207, 209, 222, 226
- externalities, xviii, 46, 47, 188, 204–206, 209, 213
- Feldman, 44, 47, 48, 57
- free-riding, 207
- Genentech, 15, 29, 35–37, 65, 132, 133, 134
- genetic engineering, 130
- high scope entrepreneurs, 97, 104
- hybrid form, 66–67, 77, 86, 194
- hybridomas, 123, 125, 130, 132, 134
- hyper-competition, 152
- incubators, 79–82
- incumbents, 34
- individual-level, 8, 23
- individual-level collaborations, 8
- industry, 6
- industry level of analysis, 34
- industry scientists, 15
- informal exchanges, 24
- information exchanges, 160, 164, 180
- innovation, 32, 119, 127, 130
- innovativeness, xiii
- institutional environment, 54, 55, 58–61, 115, 155, 176, 194, 203, 212
- intellectual commons, 53, 69, 139
- intellectual property, xi, xiii, xv, xvi, 6, 9, 13–19, 24–28, 37, 40–42, 51–60, 79, 84, 88, 91, 93, 111, 114–119, 130, 135, 138–139, 145–146, 154, 157, 159, 170–171, 177, 178–180, 185–186, 204, 206, 212–214
- intellectual property rights, xiii, xv, xvi, 6, 18, 25, 28, 42, 52, 53, 55, 56, 58, 59, 60, 79, 88, 91, 93, 114, 115, 118, 119, 138, 139, 145, 146, 154, 157, 172, 177, 178, 180, 185, 186, 204, 214
- interorganizational collaborations, xiii
- interorganizational networks, xiii
- interorganizational ties, 21
- interpersonal ties, 21
- inventions, xv, xvi, 17, 30, 42, 60, 64, 79, 89, 91–93, 96–97, 104, 112, 115–119, 124–128, 132, 138, 154, 177, 178, 183–185, 212
- IPO, 38
- isomorphism, 166
- knowledge, i, iii, xvi, 1, 2, 20, 46, 61, 65, 82, 115, 158, 161, 164, 189, 190
- knowledge creation, xiv, xv, 1, 2, 42, 58, 65, 77, 87, 115, 187, 194, 211–213, 225
- knowledge-intensive industries, xv, 39, 54, 61, 140, 211, 222, 226
- knowledge-intensive organizations, 2
- knowledge transfer, 82, 140, 150, 208
- Köhler and Milstein, 118, 123–125, 137
- Kornberg, 23
- large pharmaceutical firms, 15
- learning, xv, 1
- learning alliance, 9
- learning-by-doing, 2, 11, 89, 165, 166
- learning processes, 2
- legitimacy, 58, 66, 68, 69, 81
- levels of analyses, xiv, 1–4
- Liebeskind, x, xi, xii, xvi, 3–14, 17–25, 29–30, 36, 40, 53, 69, 74–79, 91–92, 111, 114–117, 127, 138, 140–141, 152–156, 161, 167, 176, 178, 182, 190, 195, 203–206, 218
- life-cycle, xviii, 196
- linear networking, 140, 158, 160
- Matthew effect, 93, 114
- Merton, 11–12, 79, 92, 93, 112, 114, 125, 138–139, 155–156, 179–180
- metaphors, 143–144
- model for networking, 159
- monoclonal antibody, 118
- multinational companies, 50
- multi-level, xiv
- multi-unit, xiv
- nanotechnology, xv, 28, 61, 63, 64, 157
- national-level impact, 52

- national systems of innovation, 88
 NBFs, xv, xvii, 4, 7–25, 29, 33–41, 49, 56, 65–77, 86, 127, 212, 218, 226
 Nelson, 91, 115–119, 128, 138, 154, 222
 network analysis, xiv
 networks of collaborations, 1
 network entry barriers, 6
 network forms, 190, 206, 210
 networks, i, x, xii, xiii, xiv, xviii, 2–10, 16, 21–34, 38–52, 58, 62, 81–89, 115, 140–144, 155, 162, 167–170, 176, 187–196, 200–226
 networks for learning, xiii
 new organizational forms, x, xv, 43, 65–70, 86, 211
 Nonaka, 11, 16, 45, 68, 72, 73, 93, 164, 219
 non-disclosure contract, 170, 171
 norms, 22
- open science, xvi, 11, 13, 42, 48–52, 69, 79, 111, 125, 138–139, 155, 165, 172, 176, 186
 opportunism, 79, 141, 160, 190, 208
 organizational boundaries, 75, 192–193, 200
 organizational evolution, 65–66
 organization-level, 23
 Owen-Smith 40–41, 43, 47, 50–52, 68, 83, 85, 141, 153–156
- paradox, 146, 191
 patent, xv, xvi
 pharmaceutical firms, 17, 32
 Pisano, 2
 policy, 13, 15, 42, 50, 52, 53, 56, 58, 76, 117, 122, 126
 Powell, x, 3–9, 24, 29, 31–32, 36–47, 50, 52, 66, 68, 69, 83, 92, 127, 140–141, 154, 156, 167, 189–190, 193, 199–200, 210, 213, 215, 219, 222
 prism-like methodology, 187, 213
 private versus public knowledge creation, xvi
 privatization, xvi
 public research, xvi
 public research organizations, 48, 51, 52, 92, 116
 publicity, 179
- R&D, xv, xvii, 4, 6, 8, 14, 16, 20–25, 30–33, 36, 41–42, 50, 52, 56, 60, 64, 69, 71, 78–79, 84, 89, 94, 140–141, 144–145, 150–153, 156–163, 167–168, 191, 193, 197, 200–208, 220–221
 R&D agreements, 9
 R&D collaborations, 23
 rationality, 143, 158–162, 166
 reciprocal interplay, 7
 recombinant DNA, i, xiii, xvi, 29, 31, 118, 119, 129
 recombination, i, xiii, xiv, xvi, xvii, 143, 169, 187
 redundancy, 163
 regions, 46
 Riemers, 132
- science organizations, 1
 scientific capability building, 93
 scientific community norms, 165
 scientific entrepreneurs, 43
 scientific entrepreneurship, i, x, xv, 84, 89, 91, 97, 111–115, 154, 212
 secrecy, 11, 75, 114, 125, 146, 150–154, 158, 159, 165, 166, 170, 176, 179, 181, 196
 selection, 66
 self-organizing, 142–143
 semiconductors, 61
 serendipity, 158, 163
 social capital, 39, 49, 81–82, 85, 226
 social networks, 24, 25, 26, 48–49, 216–217
 star scientists, 43
 strategic alliance, xvii, 220
 structure of science, 2
 Swanson, 29, 66, 132, 133
- tacit knowledge, 44–45, 64, 83, 89, 162–164, 190, 219–220
 technology transfer, x, xvii, 14, 17–18, 24, 28, 40–45, 49, 54, 78–79, 80, 82, 85, 89, 94–95, 119–120, 125, 140, 144–148, 150, 157–158, 169, 171, 179–181

Cambridge University Press

978-0-521-87248-5 - Networks for Learning and Knowledge Creation in Biotechnology

Amalya Lumerman Oliver

Index

[More information](#)

252

Index

technology-transfer offices, 42–43

technology-transfer personnel,
14, 21

triple helix, 41

trust, xi, xv, xvii, 158, 161, 164,
169, 173–178, 181, 217

calculative trust, 173

process-based trust, 164, 173, 175

value-based trust, 173

universities, 15, 23, 39, 42

university scientists, 20

university spin-offs, 83, 85

university–industry alliances, 140

university–industry technology
transfer, xv, xvii

value capture, 194

venture capital, 37–39, 44, 51–52, 55,
57, 60, 65, 80, 86, 132, 134,
200, 202Zucker and Darby, 35, 43, 63,
91, 92